⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AVIR News
Atea Pharmaceuticals, Inc. Common Stock
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
globenewswire.com
AVIR
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
globenewswire.com
AVIR
Form 8-K
sec.gov
AVIR
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
AVIR
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
globenewswire.com
AVIR
Form 8-K
sec.gov
AVIR
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
AVIR
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
globenewswire.com
AVIR
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
globenewswire.com
AVIR
AvAir Earns Parts Supplier of the Year for an Unprecedented Sixth Consecutive Year USA - English USA - English
prnewswire.com
AVIR